Galapagos NV (NASDAQ:GLPG) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET

Company Participants

Sofie Van Gijsel - Senior Director of Investor Relations

Paul Stoffels - Chief Executive Officer

Bart Filius - Chief Operating Officer & Chief Financial Officer

Walid Abi-Saab - Chief Medical Officer

Michele Manto - Chief Commercial Officer

Conference Call Participants

Brian Abrahams - RBC Capital Markets

Jason Gerberry - Bank of America

Charlie Mabbutt - Bernstein

James Gordon - JPMorgan

Matthew Harrison - Morgan Stanley

Phil Nadeau - Cowen & Co

Jeroen Van den Bossche - KBC Securities

Dane Leone - Raymond James

Rosie Turner - Jefferies

Operator

Good day and thank you for standing by. Welcome to the First Half 2022 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Sofie Van Gijsel. Please go ahead.

Sofie Van Gijsel

Thank you, operator and welcome all to the audio webcast of Galapagos' H1 2022 results. I'm Sofie Van Gijsel, Investor Relations, representing the reporting team at Galapagos. This recorded webcast is accessible via Galapagos website homepage and will be available for download and replay later on today.

I would like to remind everyone that we will be making forward-looking statements during today's webcast. These forward-looking statements include remarks concerning future developments of the pipeline and our company and possible changes in the industry and competitive environment. The company's forward-looking statements involve risks and uncertainties. Galapagos' actual results may differ maturely from the results expressed or implied in these statements.

Today's speakers will be Paul Stoffels, CEO; and Bart Filius, COO and President. Paul will discuss the highlights of H1 and Bart will go over the operational and financial results. You will see a presentation on the screen. We estimate that the prepared remarks will take about 20 minutes. Then we'll open it up to Q&A with Paul and Bart joined by Walid Abi-Saab, Chief Medical Officer; and Michele Manto, Chief Commercial Officer.

And with that, I'll now turn it over to Paul.

Paul Stoffels

Thank you, Sofie and welcome to this first half review of the year. Let me say, I think we have made very good progress and we'll hope to give you a good insight on where we are with the company. We'll focus on the full half year but first on Q1, you probably have seen that and remember that JYSELECA was approved in the U.K. and Japan in -- for UC and that practice U started on all JAK inhibitors and we'll come back to that later on. That review is ongoing and we'll expect the information by the end of the year.